Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/25494006/ below:

Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013

Affiliations

• ¹ Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia2Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia3Leonard Davis Institute of Health E.
• ² HealthCore, Wilmington, Delaware.
• ³ Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia5Division of General Internal Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia6Center for Health Equity Research and.
• ⁴ Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
• ⁵ WellPoint Inc, Indianapolis, Indiana.
• ⁶ Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.

• PMID: 25494006
• PMCID: PMC4271796
• DOI: 10.1001/jama.2014.16616

Item in Clipboard

Justin E Bekelman et al. JAMA. 2014.

• ¹ Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia2Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia3Leonard Davis Institute of Health E.
• ² HealthCore, Wilmington, Delaware.
• ³ Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia5Division of General Internal Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia6Center for Health Equity Research and.
• ⁴ Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
• ⁵ WellPoint Inc, Indianapolis, Indiana.
• ⁶ Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.

• PMID: 25494006
• PMCID: PMC4271796
• DOI: 10.1001/jama.2014.16616

Item in Clipboard

Importance: Based on randomized evidence, expert guidelines in 2011 endorsed shorter, hypofractionated whole breast irradiation (WBI) for selected patients with early-stage breast cancer and permitted hypofractionated WBI for other patients.

Objectives: To examine the uptake and costs of hypofractionated WBI among commercially insured patients in the United States.

Design, setting, and participants: Retrospective, observational cohort study, using administrative claims data from 14 commercial health care plans covering 7.4% of US adult women in 2013, we classified patients with incident early-stage breast cancer treated with lumpectomy and WBI from 2008 and 2013 into 2 cohorts: (1) the hypofractionation-endorsed cohort (n = 8924) included patients aged 50 years or older without prior chemotherapy or axillary lymph node involvement and (2) the hypofractionation-permitted cohort (n = 6719) included patients younger than 50 years or those with prior chemotherapy or axillary lymph node involvement.

Exposures: Hypofractionated WBI (3-5 weeks of treatment) vs conventional WBI (5-7 weeks of treatment).

Main outcomes and measures: Use of hypofractionated and conventional WBI, total and radiotherapy-related health care expenditures, and patient out-of-pocket expenses. Patient and clinical characteristics included year of treatment, age, comorbid disease, prior chemotherapy, axillary lymph node involvement, intensity-modulated radiotherapy, practice setting, and other contextual variables.

Results: Hypofractionated WBI increased from 10.6% (95% CI, 8.8%-12.5%) in 2008 to 34.5% (95% CI, 32.2%-36.8%) in 2013 in the hypofractionation-endorsed cohort and from 8.1% (95% CI, 6.0%-10.2%) in 2008 to 21.2% (95% CI, 18.9%-23.6%) in 2013 in the hypofractionation-permitted cohort. Adjusted mean total health care expenditures in the 1 year after diagnosis were $28,747 for hypofractionated and $31,641 for conventional WBI in the hypofractionation-endorsed cohort (difference, $2894; 95% CI, $1610-$4234; P < .001) and $64,273 for hypofractionated and $72,860 for conventional WBI in the hypofractionation-permitted cohort (difference, $8587; 95% CI, $5316-$12,017; P < .001). Adjusted mean total 1-year patient out-of-pocket expenses were not significantly different between hypofractionated vs conventional WBI in either cohort.

Conclusions and relevance: Hypofractionated WBI after breast conserving surgery increased among women with early-stage breast cancer in 14 US commercial health care plans between 2008 and 2013. However, only 34.5% of patients with hypofractionation-endorsed and 21.2% with hypofractionation-permitted early-stage breast cancer received hypofractionated WBI in 2013.

PubMed Disclaimer

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Liu and Barron and Ms Sylwestrzak reported that they are employees of HealthCore, which is a wholly-owned WellPoint subsidiary. Dr Malin reported that she is an employee of WellPoint.

Definition of Study Cohorts and…

Definition of Study Cohorts and Reasons for Exclusionsa ^a Initial inclusion criteria included…

Definition of Study Cohorts and Reasons for Exclusionsa ^a Initial inclusion criteria included that women be enrollees of commercial or Medicare Advantage plans, be at least 18 years old, have a diagnosis code for breast cancer, have been treated with lumpectomy, and have any code for radiation therapy appearing within 12 months of lumpectomy, and treated between 2008 and 2013. ^b Exclusions applied sequentially. Patients could be excluded for more than 1 reason.

Hypofractionated Whole Breast Irradiation After…

Hypofractionated Whole Breast Irradiation After Breast Conserving Surgery Among Patients With Early-Stage Breast…

Hypofractionated Whole Breast Irradiation After Breast Conserving Surgery Among Patients With Early-Stage Breast Cancer in 14 Commercial Health Plans, 2008 to 2013

• Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.

  Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE, Kelly P, Ludwig M, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Baumann D, Thompson AM, Amaya D, Davis T, Guerra W, Hamblin L, Hortobagyi G, Hunt KK, Buchholz TA, Smith BD. Shaitelman SF, et al. JAMA Oncol. 2015 Oct;1(7):931-41. doi: 10.1001/jamaoncol.2015.2666. JAMA Oncol. 2015. PMID: 26247543 Free PMC article. Clinical Trial.

• Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials.

  Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Jagsi R, et al. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1001-9. doi: 10.1016/j.ijrobp.2014.09.032. Int J Radiat Oncol Biol Phys. 2014. PMID: 25539365

• Association of Utilization Management Policy With Uptake of Hypofractionated Radiotherapy Among Patients With Early-Stage Breast Cancer.

  Parikh RB, Fishman E, Chi W, Zimmerman RP, Gupta A, Barron JJ, Sylwestrzak G, Bekelman JE. Parikh RB, et al. JAMA Oncol. 2020 Jun 1;6(6):839-846. doi: 10.1001/jamaoncol.2020.0449. JAMA Oncol. 2020. PMID: 32297905 Free PMC article.

• Hypofractionated radiation treatment in the management of breast cancer.

  Gupta A, Ohri N, Haffty BG. Gupta A, et al. Expert Rev Anticancer Ther. 2018 Aug;18(8):793-803. doi: 10.1080/14737140.2018.1489245. Epub 2018 Jun 26. Expert Rev Anticancer Ther. 2018. PMID: 29902386 Free PMC article. Review.

• Alternatives to Standard Fractionation Radiation Therapy After Lumpectomy: Hypofractionated Whole-Breast Irradiation and Accelerated Partial-Breast Irradiation.

  Ohri N, Haffty BG. Ohri N, et al. Surg Oncol Clin N Am. 2018 Jan;27(1):181-194. doi: 10.1016/j.soc.2017.07.006. Surg Oncol Clin N Am. 2018. PMID: 29132560 Review.

• Impact of a Novel Bioabsorbable Implant on Radiation Treatment Planning for Breast Cancer.

  Cross MJ, Lebovic GS, Ross J, Jones S, Smith A, Harms S. Cross MJ, et al. World J Surg. 2017 Feb;41(2):464-471. doi: 10.1007/s00268-016-3711-y. World J Surg. 2017. PMID: 27709273

• Implementation and utilization of hypofractionation for breast cancer.

  Gilbo P, Potters L, Lee L. Gilbo P, et al. Adv Radiat Oncol. 2018 Apr 9;3(3):265-270. doi: 10.1016/j.adro.2018.04.001. eCollection 2018 Jul-Sep. Adv Radiat Oncol. 2018. PMID: 30202795 Free PMC article.

• Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial.

  Xie J, Xu F, Zhao Y, Cai G, Lin X, Zhu Q, Lin Q, Yao Y, Xu C, Cai R, Wang S, Tang X, Chen C, Zheng S, Chen M, Chen M, Qian X, Shen C, Li J, Xu H, Xu F, Han Y, Li M, Ou D, Shen KW, Qi WX, Cao L, Huang X, Chen J. Xie J, et al. BMJ Open. 2022 Sep 1;12(9):e062034. doi: 10.1136/bmjopen-2022-062034. BMJ Open. 2022. PMID: 36581983 Free PMC article.

• Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial.

  Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Amaya DN, Shen Y, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Shaitelman SF, et al. J Clin Oncol. 2018 Oct 31;36(35):JCO1800317. doi: 10.1200/JCO.18.00317. Online ahead of print. J Clin Oncol. 2018. PMID: 30379626 Free PMC article.

• Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.

  Venigalla S, Guttmann DM, Jain V, Sharma S, Freedman GM, Shabason JE. Venigalla S, et al. Clin Breast Cancer. 2018 Oct;18(5):e899-e908. doi: 10.1016/j.clbc.2018.02.009. Epub 2018 Feb 21. Clin Breast Cancer. 2018. PMID: 29550285 Free PMC article.

1. 1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128. - PMC - PubMed
2. 1. Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? J Clin Oncol. 2010;28(21):3437–3441. - PubMed
3. 1. Darby S, McGale P, Correa C, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716. - PMC - PubMed
4. 1. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–520. - PubMed
5. 1. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94(15):1143–1150. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3